Embryos and Parkinson's Disease

Hitchcock, Edward; Clough, Chris; Hughes, R. C.; Kenny, Brendan

doi:10.1016/s0140-6736(88)92088-0

Cited by 67 publications

(11 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both had been treated with levodopa with decreasing effect [11,12]. A sur prising feature was the immediate improvement in symptoms within minutes after injection.…”

Section: Resultsmentioning

confidence: 99%

Stereotactic Implantation of Fetal Mesencephalon

Hitchcock

Kenny

Clough

et al. 1990

Stereotact Funct Neurosurg

Self Cite

View full text Add to dashboard Cite

show abstract

“…Both had been treated with levodopa with decreasing effect [11,12]. A sur prising feature was the immediate improvement in symptoms within minutes after injection.…”

Section: Resultsmentioning

confidence: 99%

Stereotactic Implantation of Fetal Mesencephalon

Hitchcock

Kenny

Clough

et al. 1990

Stereotact Funct Neurosurg

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, the Chinese team reported a reduction in limb tremors and rigidity on the third day after the surgery, with satisfactory control of parkinsonism confirmed after eight months of diagnostic monitoring. Moreover, a United Kingdom group published a case report of fetal tissue transplantation for PD in 1988 [71] . The authors stated that two patients (a 60-year-old female and 41-year-old male) with early and late parkinsonism, respectively, showed immediate improvements in motion symptoms following the administration of a mesencephalic cell suspension (fetal age unknown).…”

Section: Mid 1980's To Early 2000'smentioning

confidence: 99%

“…Such clinical results have encouraged many researchers worldwide to apply this therapeutic approach as a treatment for PD. Namely, fetal brain tissue transplantation, which began in China [2,80] , has been attempted in Canada [81] , Cuba [82] , the Czech Republic [83] , France [84] , Mexico [1] , Poland [85] , Slovakia [86] , Spain [87,88] , United Kingdom [71,89] , United States [2,3,73,77,90,91] , and USSR (currently Russia) [92] . Moreover, the Network of European CNS Transplantation and Restoration (NECTAR) was founded in 1990 to bring together European groups who share the common goal of protecting, repairing and restoring the central nervous system damage resulting from degenerative diseases and/or injury [93] .…”

Section: Mid 1980's To Early 2000'smentioning

confidence: 99%

Fetal stem cell transplantation: Past, present, and future

Ishii

Eto

2014

WJSC

View full text Add to dashboard Cite

Since 1928, human fetal tissues and stem cells have been used worldwide to treat various conditions. Although the transplantation of the fetal midbrain substantia nigra and dopaminergic neurons in patients suffering from Parkinson's disease is particularly noteworthy, the history of other types of grafts, such as those of the fetal liver, thymus, and pancreas, should be addressed as there are many lessons to be learnt for future stem cell transplantation. This report describes previous practices and complications that led to current clinical trials of isolated fetal stem cells and embryonic stem (ES) cells. Moreover, strategies for transplantation are considered, with a particular focus on donor cells, cell processing, and the therapeutic cell niche, in addition to ethical issues associated with fetal origin. With the advent of autologous induced pluripotent stem cells and ES cells, clinical dependence on fetal transplantation is expected to gradually decline due to lasting ethical controversies, despite landmark achievements.

show abstract

“…These promising findings led to the initiation of clinical trials in the late 1980s, in which fetal ventral mesencephalic tissue from aborted human fetuses were transplanted into patients with PD [180][181][182]. The majority of the early studies were open-label, uncontrolled trials, which reported a remarkable ability of transplanted human fetal dopaminergic cells to survive and provide clinically meaningful improvement that in some cases could replace pharmacological therapies [183][184][185][186][187][188][189][190][191][192].…”

Section: Fetal Neural Tissue Transplantation In Parkinson's Diseasementioning

confidence: 99%

Mesenchymal Stem Cell-Based Therapies for Parkinson’s Disease: Progress, Controversies and Lessons for the Future

Khoo¹,

Tao²,

D.F.³

2011

J Stem Cell Res Ther

View full text Add to dashboard Cite

Scientific and clinical research interest in mesenchymal stem cells (MSCs) has increased exponentially since the identification of MSCs in the bone marrow. It is now recognized that MSCs possess the in vitro characteristics of stem cells with the abilities to proliferate, symmetrically divide, and produce multi-lineage mesodermal derivatives, making MSCs attractive candidates for use in potential cellular therapies. Furthermore, MSCs can be relatively easily isolated and expanded in culture with low tumorigenicity and teratoma formation, and have been reported to display immunomodulatory properties that may be advantageous in clinical transplantation. Discovery of the ability of MSCs to differentiate into cells of non-mesodermal tissues, particularly neural cells, has also raised the possibility of utilizing MSCs in regenerative and reparative therapies for neurological disorders. However, a number of hurdles remain to be resolved, including conflicting findings concerning the capacity of MSCs to suppress immune responses and contribute to multiple tissue lineages, highlighting the need for a greater understanding of mechanisms underlying the observed phenomena. In this review we will discuss: (1) recent advances in our understanding of MSC plasticity/transdifferentiation and immunomodulatory properties; (2) evidence for cell-based therapies, in particular MSC-based therapies for Parkinson's disease; and (3) current challenges and potential strategies for the utilization of MSCs in the treatment of Parkinson's disease.

show abstract

Embryos and Parkinson's Disease

Cited by 67 publications

References 1 publication

Stereotactic Implantation of Fetal Mesencephalon

Stereotactic Implantation of Fetal Mesencephalon

Fetal stem cell transplantation: Past, present, and future

Mesenchymal Stem Cell-Based Therapies for Parkinson’s Disease: Progress, Controversies and Lessons for the Future

Contact Info

Product

Resources

About